7 results
Anti-IL6 Agents (Tocilizumab, Siltuximab) in COVID19

IL-6 activates T cells and macrophages, among other cell types (see
Siltuximab) in COVID19 ... -6 activates T cells ... Cytokine Activation Syndrome ... #Pharmacology # ... Management #Medications
Drugs Used for the Treatment of COVID-19 Infection

** Editor Note (from ophthalmology MD input) - Hydroxychloroquine/chloroquine
the Treatment of COVID ... Editor Note (from ophthalmology ... highlighted circle= clinical ... #Pharmacology # ... Table #Management
Immune Reconstitution Inflammatory Syndrome - Overview of IRIS

What Is IRIS?
	• A state of hyperinflammatory response that
Reconstitution Inflammatory Syndrome ... noncompliance • Clinical ... initiation Clinical ... #Inflammatory #Syndrome ... Differential #Diagnosis #Management
Sjogren's Syndrome Overview

Epidemiology:
• F > M: 9:1
• 5-6th Decades (can be any age)

Autoimmune exocrinopathy multisystemic disease
Sjogren's Syndrome ... SLE • Mikulicz syndrome ... ducts Clinical ... lubricants • Pharmacologic ... Rheumatology #Diagnosis #Management
IDSA Recommendations for Treating Coccidiodomycosis in HIV-AIDS
Treating Mild Infections (Such As Focal Pneumonia or asymptomatic patients
CD4 count <250 cells ... • Use until clinical ... Prevention #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Histoplasma Capsulatum Infections in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
CD4 count <150 cells ... weeks or until clinically ... Prevention #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
CD4 count <50 cells ... disease based on clinical ... Prevention #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology